Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.
Between February 1994 and November 1998, 56 oncology patients infected with vancomycin-resistant enterococci (VRE) were treated with quinopristin-dalfopristin (Q-D) plus minocycline (MIN). Infections included bacteremia, urinary tract infection, pneumonia, and wound infection. The response rate was 68%, and the most frequent adverse event was arthralgia or myalgia (36%). Q-D-MIN is effective for VRE infection in cancer patients but is associated with a substantial frequency of arthralgia or myalgia.
Raad
I
I
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4095, USA. iraad@mdanderson.org
Hachem
R
R
Hanna
H
H
Girgawy
E
E
Rolston
K
K
Whimbey
E
E
Husni
R
R
Bodey
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D004359:Drug Therapy, Combination; D016983:Enterococcus / Q000187:drug effects*; D013293:Enterococcus faecalis; D016984:Enterococcus faecium; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications; D010146:Pain / Q000139:chemically induced; D020713:Vancomycin Resistance; D014769:Virginiamycin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D014769:Virginiamycin; C113825:quinupristin; D008911:Minocycline